BioSpace News Archive

After identifying structural variations in the 19-gauge filter needle included in some eye injection kits, Apellis has advised doctors to only use 18-gauge kits already in circulation and that will be distributed.

Spurred by an “inadvertent” disclosure, Roche’s Genentech on Wednesday released interim and immature overall survival findings for its anti-TIGIT antibody tiragolumab in non-small cell lung cancer.

To successfully compete against one another and Big Pharma for top talent, biotech companies need to do a better job of selling themselves.

Under the $1.4 billion Project NextGen initiative, Regeneron was awarded a $326 million grant for its preventive monoclonal antibody, while Johnson & Johnson got $10 million to bankroll startups.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-June 2023.

Genentech, a member of the Roche Group, has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® versus Tecentriq alone as an initial treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

NorthX Biologics AB, a leading Nordic development and manufacturing organisation with a focus on advanced biologics, CGT and vaccines, announces that it has appointed Dr Janet Hoogstraate as its new Chief Executive Officer with immediate effect.

Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is pleased to announce a significant milestone following receipt of FDA Investigational Device Exemption approval to conduct a staged pivotal clinical trial for its Duett Vascular Graft System in the United States.

Johnson & Johnson announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. common stock owned by Johnson & Johnson.

Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the companies’ supplemental New Drug Application for XTANDI® for the treatment of patients with non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.